MeiraGTx (NASDAQ:MGTX) CFO Sells $212,880.00 in Stock

MeiraGTx Holdings PLC (NASDAQ:MGTX) CFO Richard Giroux sold 24,000 shares of MeiraGTx stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $8.87, for a total value of $212,880.00. Following the completion of the transaction, the chief financial officer owned 829,494 shares in the company, valued at approximately $7,357,611.78. The trade was a 2.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

MeiraGTx Trading Up 0.1%

Shares of MGTX opened at $8.75 on Friday. The firm has a market cap of $703.94 million, a price-to-earnings ratio of -4.29 and a beta of 1.34. MeiraGTx Holdings PLC has a 52-week low of $4.55 and a 52-week high of $9.44. The company has a debt-to-equity ratio of 26.29, a quick ratio of 0.88 and a current ratio of 0.88. The business’s fifty day moving average is $7.92 and its 200-day moving average is $7.08.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. The business had revenue of $3.69 million for the quarter, compared to analyst estimates of $8.00 million. MeiraGTx had a negative return on equity of 314.44% and a negative net margin of 415.39%. Equities analysts anticipate that MeiraGTx Holdings PLC will post -1.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MGTX. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of MeiraGTx in a research report on Friday, August 15th. Raymond James Financial began coverage on MeiraGTx in a research report on Tuesday. They set a “strong-buy” rating and a $29.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of MeiraGTx in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded MeiraGTx from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MGTX. GAMMA Investing LLC lifted its holdings in MeiraGTx by 3,606.7% during the 1st quarter. GAMMA Investing LLC now owns 4,448 shares of the company’s stock worth $30,000 after buying an additional 4,328 shares during the period. Rhumbline Advisers lifted its holdings in MeiraGTx by 6.1% during the 1st quarter. Rhumbline Advisers now owns 58,227 shares of the company’s stock worth $395,000 after buying an additional 3,336 shares during the period. Janney Montgomery Scott LLC lifted its holdings in MeiraGTx by 62.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 122,220 shares of the company’s stock worth $829,000 after buying an additional 46,902 shares during the period. Acuitas Investments LLC acquired a new position in MeiraGTx during the 1st quarter worth about $286,000. Finally, Bank of New York Mellon Corp lifted its holdings in MeiraGTx by 3.7% during the 1st quarter. Bank of New York Mellon Corp now owns 110,567 shares of the company’s stock worth $750,000 after buying an additional 3,985 shares during the period. 67.48% of the stock is owned by institutional investors and hedge funds.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.